The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

OBJECTIVE We studied time in tight range (TITR)(70–140 mg/dL) in real-world users of the
MiniMed 780G system (MM780G). RESEARCH DESIGN AND METHODS CareLink …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

The role of automated insulin delivery systems in diabetes is expanding. Hybrid closed-loop
systems are being used in routine clinical practice for treating people with type 1 diabetes …

Objective: Severe hypoglycemia (SH) and diabetic ketoacidosis (DKA) remain significant
risks with intensive insulin therapy. While these adverse event (AE) rates are generally very …

The concept of maintaining blood glucose levels within the 70–180 mg/dL range, known as
time-in-range, has raised questions regarding its representation of true physiological …

Background: Pivotal trials of diabetes technologies have demonstrated glycemic
improvements; however, these trials include patients of limited diversity and ranges of …

The t: slim X2 insulin pump with Control-IQ technology (Control-IQ) advanced hybrid closed-
loop automated insulin delivery system was evaluated in this prospective single-arm trial …

Background: We assessed changes in glycemic control and person-reported outcome
measures (PROMs) with t: slim X2 insulin pump with Control-IQ technology use among …